BR112015014262A8 - formulação farmacêutica, dispositivo adaptado para distribuição intranasal de uma formulação farmacêutica, e, uso de uma formulação farmacêutica - Google Patents

formulação farmacêutica, dispositivo adaptado para distribuição intranasal de uma formulação farmacêutica, e, uso de uma formulação farmacêutica Download PDF

Info

Publication number
BR112015014262A8
BR112015014262A8 BR112015014262A BR112015014262A BR112015014262A8 BR 112015014262 A8 BR112015014262 A8 BR 112015014262A8 BR 112015014262 A BR112015014262 A BR 112015014262A BR 112015014262 A BR112015014262 A BR 112015014262A BR 112015014262 A8 BR112015014262 A8 BR 112015014262A8
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
device adapted
intranasal delivery
inflammatory
formulation
Prior art date
Application number
BR112015014262A
Other languages
English (en)
Other versions
BR112015014262A2 (pt
Inventor
Scott Levin Daren
Michele Ignar Diane
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR112015014262A2 publication Critical patent/BR112015014262A2/pt
Publication of BR112015014262A8 publication Critical patent/BR112015014262A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

1 / 1 resumo “formulaã‡ãƒo farmacãšutica, dispositivo adaptado para distribuiã‡ãƒo intranasal de uma formulaã‡ãƒo farmacãšutica, mã‰todo de tratamento de rinite alã‰rgica, uso de uma formulaã‡ãƒo farmacãšutica, e, mã‰todo para o tratamento de condiã‡ãƒo inflamatã“ria e/ou alã‰rgica” a presente invenã§ã£o se refere a formulaã§ãµes farmacãªuticas compreendendo um composto glicocorticoide anti-inflamatã³rio da sã©rie de androstano e levocabastina, e um antagonista h /antialã©rgico. a presente 1 invenã§ã£o tambã©m se refere aos usos terapãªuticos destes, particularmente para o tratamento de condiã§ãµes inflamatã³rias e alã©rgicas, especificamente rinite.
BR112015014262A 2012-12-17 2013-12-13 formulação farmacêutica, dispositivo adaptado para distribuição intranasal de uma formulação farmacêutica, e, uso de uma formulação farmacêutica BR112015014262A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737927P 2012-12-17 2012-12-17
US201361867794P 2013-08-20 2013-08-20
PCT/EP2013/076486 WO2014095602A1 (en) 2012-12-17 2013-12-13 Combination of levocabastine and fluticasone furoate for the treatment of inflammatory and/or allergic conditions

Publications (2)

Publication Number Publication Date
BR112015014262A2 BR112015014262A2 (pt) 2017-07-11
BR112015014262A8 true BR112015014262A8 (pt) 2019-10-08

Family

ID=49759334

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015014262A BR112015014262A8 (pt) 2012-12-17 2013-12-13 formulação farmacêutica, dispositivo adaptado para distribuição intranasal de uma formulação farmacêutica, e, uso de uma formulação farmacêutica

Country Status (11)

Country Link
US (1) US9675624B2 (pt)
EP (1) EP2931249B1 (pt)
JP (1) JP6294893B2 (pt)
KR (1) KR20150095896A (pt)
CN (1) CN104869980A (pt)
AU (1) AU2013363876B9 (pt)
BR (1) BR112015014262A8 (pt)
CA (1) CA2893654A1 (pt)
ES (1) ES2722926T3 (pt)
RU (1) RU2652352C2 (pt)
WO (1) WO2014095602A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102015206486B4 (de) * 2015-04-10 2023-06-01 Adidas Ag Schuh, insbesondere Sportschuh, und Verfahren zur Herstellung desselben
USD783264S1 (en) 2015-09-15 2017-04-11 Adidas Ag Shoe
SG11202012005VA (en) * 2018-06-08 2021-01-28 Toko Yakuhin Kogyo Co Ltd Fluticasone furoate nasal preparation composition
EP3769753B1 (en) * 2019-07-23 2021-11-17 Nicox Ophthalmics, Inc. Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
RU2736082C1 (ru) * 2019-12-02 2020-11-11 федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации Фармацевтическая композиция противоаллергического и противовоспалительного действия для интраназального применения

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
LT2486942T (lt) * 2004-11-24 2019-01-25 Meda Pharmaceuticals Inc. Kompozicijos, apimančios azelastiną ir jų panaudojimo būdai
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
WO2009050159A1 (en) * 2007-10-16 2009-04-23 Glaxo Group Limited Combination of fluticasone furoate with 4- [ (4-chl0r0phenyl)methyl] -2- ({ (2r)-i- [4-(4-{ [3-(hexahydr0-lh-azepin-l-yl) propyl ] oxy} phenyl) butyl] -2-pyrrolidinyl}methyl) -1 (2h) - phthalaz inone
CN101757625A (zh) * 2008-11-28 2010-06-30 天津金耀集团有限公司 环糊精包合皮质激素和h1受体拮抗剂的鼻用药物组合物

Also Published As

Publication number Publication date
WO2014095602A1 (en) 2014-06-26
CA2893654A1 (en) 2014-06-26
KR20150095896A (ko) 2015-08-21
JP2016502991A (ja) 2016-02-01
RU2652352C2 (ru) 2018-04-25
JP6294893B2 (ja) 2018-03-14
AU2013363876B9 (en) 2016-12-15
AU2013363876B2 (en) 2016-12-01
ES2722926T3 (es) 2019-08-20
US9675624B2 (en) 2017-06-13
RU2015121039A (ru) 2017-01-23
AU2013363876A1 (en) 2015-07-16
BR112015014262A2 (pt) 2017-07-11
US20150297614A1 (en) 2015-10-22
EP2931249A1 (en) 2015-10-21
EP2931249B1 (en) 2019-01-16
CN104869980A (zh) 2015-08-26

Similar Documents

Publication Publication Date Title
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
BR112013031794A2 (pt) novos derivados de oxintomodulina e composição farmacêutica para o tratamento da obesidade compreendendo os mesmos
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
BR112013013167A8 (pt) inibidores de bromodomínio e usos dos mesmos
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
BR112015021222A2 (pt) inibidores de ras e usos dos mesmos
GT201400085A (es) Profármaco de adrenomedulina basado en polietilenglicol y su uso
NI201500115A (es) Estra-1,3,5(10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
CL2016001543A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas.
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
BR112015015870A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
BR112015014262A8 (pt) formulação farmacêutica, dispositivo adaptado para distribuição intranasal de uma formulação farmacêutica, e, uso de uma formulação farmacêutica
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
BR112014016389A8 (pt) composições e uso das mesmas para o tratamento de distúrbios e doenças hepáticas
BR112017023432A2 (pt) Derivados de ácido propiônico tetra- hidronaftiridinila e usos do mesmo
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
BR112016028518A2 (pt) composições farmacêuticas que compreendem dgla e uso do mesmo
BR112017008867A2 (pt) inibidores de proteína quinases
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements